TFOX beats FOLFOX in 1st-line tx for HER2– advanced gastric/GOJ adenoca (PRODIGE 51). OS: 15.1 vs 12.7 mo (p=0.048).ORR: 62% vs 53%.Toxicity ↑ but manageable in ECOG 0, age <70. New non-targeted option?. 📄 #GIoncology #TFOX #GastricCancer

BREAKWATER trial: First-line encorafenib + cetuximab + mFOLFOX6 doubles OS in BRAF V600E mCRC vs SOC (30.3 vs 15.1 mo; HR 0.49; P<0.0001). PFS also improved (12.8 vs 7.1 mo). Clear shift in standard. 🔗 #GIoncology #CRC #HPBsurgeon

Neoadjuvant PD-1 blockade (dostarlimab):.✅ 100% cCR in dMMR rectal cancer.✅ 65% cCR in nonrectal dMMR (colon, HPB, urothelial).✅ 92% 2-yr RFS, no missed surgery window. Organ preservation is real. 📄 #GIoncology #HPBsurgeon #MSIhigh #SurgicalOncology

Neoadjuvant PD-1 blockade (dostarlimab):.✅ 100% cCR in dMMR rectal cancer.✅ 65% cCR in nonrectal dMMR (colon, HPB, urothelial).✅ 92% 2-yr RFS, no missed surgery window. Organ preservation is real. 📄 #GIoncology #HPBsurgeon #MSIhigh #SurgicalOncology

Atezolizumab + trastuzumab + XELOX boosts pCR to 38% vs 14% in resectable ERBB2+ GC/GEJ adenoca. First RCT in periop setting—no new safety signals. Phase 3 next?. 🔗

Maintaining ≥80% RDI with FOLFOXIRI+bev matters. In TRIBE/2 pooled data:.🟢 ORR 70% vs 58%.🟢 OS 33.6 vs 22.9 mo (HR 0.61).🟢 PFS 13.7 vs 10.8 mo (HR 0.67). <80% RDI? No gain over doublets. 🔗 #GIonc #ColorectalCancer #FOLFOXIRI #OncoTwitter

After decades of use, somatostatin analogues show **no significant reduction** in clinically relevant POPF post-pancreatic surgery (OR 0.89, *P*=0.44). No benefit in high-risk cases or with pasireotide. Time to rethink routine SSA prophylaxis?.🧾 [

The 2025 ACR Criteria re-emphasize CT Colonography (CTC) as an appropriate CRC screening tool for average-risk pts ≥45 yrs when colonoscopy isn’t feasible. 🔎 CTC sensitivity: >90% for large adenomas/cancers.🔄 Ideal in incomplete scopes, contraindications, or refusal cases.🚫

The 2025 ACR Appropriateness Criteria for anal SCC reaffirm MRI pelvis w/ IV contrast and FDG-PET/CT as top choices for initial staging. 🚨 FDG-PET/CT altered nodal staging in 28% and treatment plans in up to 59%. 🔍 CT has limited role for local staging—low sensitivity

How do current guidelines fare after EUS-FNA diagnosis of incidental pancreatic mucinous neoplasms?. A new study (n=140) shows ESG-2018 offers the best balance—highest accuracy with only 15% unnecessary surgeries and 17% missed malignancies. In contrast:. AGA-2015 avoids

🧵In a landmark consensus from ESGAR, ESUR, PSOGI & EANM, STIR-DWI MRI emerges as the most accurate tool for preop assessment of peritoneal metastases (PM) in CRC & OC. CT remains the workhorse for initial screening—but underestimates PCI by up to 33%. FDG PET/CT misses

US remains the cornerstone for HCC surveillance—cost-effective and mortality-reducing. But not all livers are created equal. The LI-RADS US Surveillance v2024 core introduces a game-changing visualization score (VIS A–C) to identify when US fails—and when to escalate to AMRI or

A sweeping multidisciplinary consensus from EORTC on colorectal liver metastases just landed. 🔹 Surgery and ablation now viewed as equally effective for ≤3 cm CRCLM. 🔹 New stratification: resectable, potentially resectable post-treatment, or never resectable—not just based on

🚨 Important update on RAMPS vs SDP for left-sided PDAC. A 2025 TSA meta-analysis (n=1,374) confirms no survival advantage of RAMPS over standard distal pancreatectomy:. OS: HR 1.33 [0.89–2.00]. DFS: HR 1.21 [0.80–1.83]. R0 rates, complications, operative time = similar. Shorter

Is it time to abandon the MIPD hype?. This new meta-analysis of 7 RCTs (n=1428) comparing MIPD (lap & robotic) vs OPD reveals:. 🩺 Mortality: 2.9% (MIPD) vs 2.6% (OPD).📉 Major morbidity: No significant difference (RR 1.18; 95% CI 0.97–1.44).🔬 R1 resection: 6.2% vs 7% (NS).⏱️

5-year data from the DYNAMIC trial confirms: ctDNA-guided adjuvant therapy (ACT) in stage II colon cancer reduces chemo use without compromising long-term outcomes. 🔹 5-year RFS: 88% (ctDNA-guided) vs 87% (standard).🔹 OS: 93.8% vs 93.3% (HR 1.05, P = 0.887).🔹 ctDNA clearance

New post hoc analysis from FIRE-3 (AIO KRK0306) sharpens how we interpret tumor biology in RAS-WT mCRC. ➡️ In 395 pts, combining primary tumor sidedness (PTS) with liver-limited disease (LLD) status better predicted OS benefit from FOLFIRI + cetuximab (Cet) vs bevacizumab (Bev).

📌 RACE-GB Trial (Int J Radiat Oncol Biol Phys, 2025).In a landmark single-center RCT from India (N=135), consolidation chemoradiotherapy (CTRT) post-4 cycles of cisplatin-gemcitabine doubled median OS in unresectable advanced gallbladder cancer (GBC) from 4 to 10 months (HR

Can we safely de-escalate treatment in early-stage anal SCC?. The ACT4 trial (PLATO platform) reports promising 6-month outcomes for T1–T2 (≤4 cm) N0 anal cancers:. Complete response: 92% (rd-IMRT) vs 87% (sd-IMRT). Grade ≥3 toxicity: 35% vs 46%. Sexual function recovery

📊 CheckMate 9DW changes the HCC landscape. In this global phase 3 RCT (n=668), nivolumab + ipilimumab demonstrated a median OS of 23.7 mo vs 20.6 mo with lenvatinib or sorafenib in first-line uHCC (HR 0.79; p=0.018). 36-mo OS: 38% vs 24%.ORR: 36% vs 13%.Median DoR: 30.4 mo vs